Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06977646

Surgical Treatment of the Patients With Restrictive Phenotype of the Hypertrophic Cardiomyopathy Without LVOT Obstruction

Hypertrophic cardiomyopathy - is an inherited disease characterized by pronounced genetic and phenotypic heterogeneity. There are two most common anatomic variants of cardiac hypertrophy: subaortic and submitral phenotypes. Subaortic phenotype is characterized by hypertrophy of the basal parts of the heart, mainly in the interventricular septum (IVS), manifesting by a high pressure gradient in the LVOT. Submitral phenotype is characterized by localization of hypertrophic zone downward to the apex and apical phenotype is without a pressure gradient in the LVOT.

The morphology, nature of hemodynamic abnormalities not well studied in patients with apical phenotype of HCM, and surgical treatment are controversial, and for those patients with advanced stage of the HF the orthotopic heart transplantations (HTx) is usually considered.

One of the surgical techniques available for this category of patients is apical myectomy. The main goal of this intervention is increasing the left ventricular volume and improving of the LV compliance with an increase of the diastolic relaxation. Limited data of such procedures in HCM patients were already published but it still requires further investigation on larger cohort of patients.

In this study, the investigators hypothesize that along with left ventricular septal hypertrophy, a small cavity is formed in patients with submittal-apical phenotype due to an increased number of hypertrophied papillary muscles. They are displaced to the apex and tightly fixed both among themselves and to the left ventricular walls. This causes a significant reduction in diastolic volume and left ventricular relaxation capacity. The present study will analyze the experience of performing resection of hypertrophied trabeculae and mobilization of papillary muscles performed through the aorta. Throw this approach procedure can be done without the need for traumatic access and suturing in the apex of the left ventricle.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertrophic apical cardiomyopathy according to medical records
  • Surgical left ventricular remodeling performed

Exclusion criteria

  • LVOT gradient greater than 30 mmHg

Treatment and study plan

Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction

Procedure

The proposed intervention is a variation of classical myectomy, but unlike it, the main substrate for resection is not only the hypertrophied interventricular septum, but the abnormal papillary muscles and interpapillary trabeculae in the left ventricular cavity

Primary outcomes

  1. Hospital mortality after undergoing trans aortic surgical left ventricular remodeling

    Time frame: Assessment by medical records during the first 28 days after surgical intervention

    Binary value: of alive/dead

Secondary outcomes

  1. left ventricular diastolic dysfunction

    Time frame: Perioperative/Periprocedural

    Diastolic left ventricular function relying on echo protocols. E/A ratio as an equation of an early transmitral flow (E wave) and a late flow with atrial contraction (A wave). An E/A ratio less than 0.75 or greater than 1.5 indicates dyastolic disfunction.

  2. Heart Failure (NYHA)

    Time frame: 1 month after surgery

    Functional class of heart failure according to New York Heart Association (NYHA) Functional Classification of heart failure

  3. Need for mechanical circulation in the postoperative period

    Time frame: Perioperative/Periprocedural

    Binary value: yes/no

  4. Freedom from re-interventions after surgical left ventricular remodeling

    Time frame: hrough study completion, an average of 1 year

    Binary value yes/no According to available medical records for the entire follow-up period

Other outcomes

  1. Search for mutations in full genomic DNA by sequencing method

    Time frame: through study completion, an average of 1 year

    Pathogenicity assessment of candidate genetic variants is performed according to the ACMG recommendations (2015) Will be performed on patients who have a preserved tissue sample suitable for whole genome sequencing

Sponsors and collaborators

Lead sponsor

Petrovsky National Research Centre of Surgery

Other

Registry information

Official study title

Retrospective Study of the Surgical Treatment Restrictive Form of the Hypertrophic Cardiomyopathy Without of the Left Ventricular Outflow Tract Obstruction

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 18, 2025
Registry last updated
Jul 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.